home / stock / sppi / sppi news


SPPI News and Press, Spectrum Pharmaceuticals Inc. From 05/06/22

Stock Information

Company Name: Spectrum Pharmaceuticals Inc.
Stock Symbol: SPPI
Market: NASDAQ
Website: sppirx.com

Menu

SPPI SPPI Quote SPPI Short SPPI News SPPI Articles SPPI Message Board
Get SPPI Alerts

News, Short Squeeze, Breakout and More Instantly...

SPPI - Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2022 financial results and provide a corporate update on Thursday, May 12, 2022 at 4:30 p....

SPPI - Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the appointment of Brittany Bradrick to its Board of Directors. Brittany is an accomplished leader with 25 years of finance, strategy and corporate de...

SPPI - Spectrum announces resubmitted Eflapegrastim BLA accepted for filing

Spectrum Pharmaceuticals (NASDAQ:SPPI) has announced that the resubmitted Biologics License Application for Eflapegrastim has been accepted for filing. The U.S. FDA has set a Prescription Drug User Fee Act goal date of Sept. 9, 2022. “The acceptance of the BLA resubmission is an import...

SPPI - HUYA, SPPI and DOYU among pre market gainers

Veru (VERU) +31% after interim results for COVID-19 therapy. SailPoint Technologies (SAIL) +30% acquisition could lead to other cyber security deals, Wedbush says. Iveda Solutions (IVDA) +28%. VNET Group (VNET) +20% receives buyout offer of $1.3333 per share. Aff...

SPPI - Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim

FDA has assigned September 9, 2022 as the PDUFA date Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the resubmitted Biologics License Application (BLA) for eflapegrastim has be...

SPPI - Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced abstract acceptance with a poster presentation at the upcoming American Association for Cancer Research (AACR) Annual Meeting, to be held in New Orlea...

SPPI - Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor for the global market. As more and more patients are diag...

SPPI - IRBT, CENN and SPPI among pre market gainers

Mercurity Fintech Holding (MFH) +65%. Fast Radius (FSRD) +21%. Nikola (NKLA) +18% after investor event. Femasys (FEMY) +13%. BiondVax Pharmaceuticals (BVXV) +13% on research pact to develop nanosized antibody therapies. Incannex Healthcare (IXHL) +12%. D-MARKET Elektronik&...

SPPI - Spectrum Pharmaceuticals (SPPI) Q4 2021 Earnings Call Transcript

Image source: The Motley Fool. Spectrum Pharmaceuticals (NASDAQ: SPPI) Q4 2021 Earnings Call Mar 17, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Spectrum Pharmaceuticals (SPPI) Q4 2021 Earnings Call Transcript ...

SPPI - Spectrum Pharmaceuticals, Inc. (SPPI) CEO Tom Riga on Q4 2021 Results - Earnings Call Transcript

Spectrum Pharmaceuticals, Inc. (SPPI) Q4 2021 Earnings Conference Call March 17, 2022, 04:30 PM ET Company Participants Kurt Gustafson - CFO Tom Riga - President & CEO Francois Lebel - EVP & Chief Medical Officer Conference Call Participants Kevin Strang - Jefferies Ed White - H.C. Wa...

Previous 10 Next 10